Related Experiment Video
Updated: Mar 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis
Ting Yuan1, Feng Zhang1, Qing-Min Yao1
1Department of Hematology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, Shandong, P.R. China.
Background:
Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain.
Methods:
We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate. The secondary outcomes were the proportions of patients in each group experiencing the adverse events including the neutropathy, fatigue, diarrhea, nausea and neutropenia.
Findings:
After final screening, six trials were considered eligible for analysis. The results showed that the overall response rate of biweekly schedule was higher than that of weekly schedule in indolent lymphoma (OR 1.691;95%CI 1.02-2.80). Furthermore, there were no significant differences between the two schedules of bortezomib for the main adverse events.
Interpretation:
The biweekly schedule of bortezomib was more effective than the weekly schedule in indolent lymphoma, with similar proportion of toxicities.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
Bioequivalence studies: Biowaivers
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence of Drugs: Drugs with Multiple Indications
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Dosage Regimens: Partial Pharmacokinetic Parameters